Do you consider GLP-1 receptor agonists for patients with alcohol use disorder who had an inadequate response to naltrexone or acamprosate?

As the research continues to evolve, have you had any success using GLP-1s in this population? Klausen M, Justesen S, Pedersen J et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. The Lancet, 407, 1687-1698 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00305-3/fulltext